The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 6, 2004, Pages 475-481

  Jannuzzo, Maria Gabriella ^a   Poggesi, Italo ^a   Spinelli, Riccardo ^a   Rocchetti, Maurizio ^a   Cicioni, Paolo ^a   Buchan, Peter ^a  

^a Pfizer Group Inc   (Italy)

Author keywords

Aromatase inhibitor; Exemestane; Hepatic impairment; Pharmacokinetics; Renal impairment

Indexed keywords

EXEMESTANE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LABORATORY TEST; LIVER FAILURE; LIVER FUNCTION; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINALYSIS;

ADMINISTRATION, ORAL; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; AROMATASE INHIBITORS; FEMALE; HUMANS; KIDNEY DISEASES; LIVER DISEASES; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSTMENOPAUSE;

EID: 2542446523     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0774-5     Document Type: Article

References (14)

1. Clemett D, Lamb HM (2000) Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59:1279
2. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31
3. Dank M (2002) The role of Aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res 8:87
4. Geigy Scientific Tables, vol. 3. Ciba-Geigy, Basle, p 329
5. Henderson JC, Canellos GP (1980) Cancer of the breast: the past decade (part 1). N Engl J Med 302:17
6. Lombardi P (2002) Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim Biophys Acta 1587:326
7. Machin D, Campbell MJ (1987) Statistical tables for the design of clinical trials. Blackwell Scientific, Oxford, pp 79-83
8. Paridaens R, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S, de Belder K (1998) Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 9:675
9. Persiani S, Broutin F, Cicioni P, Stefanini P, Strolin Benedetti M (1996) Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay. Eur J Pharm Sci 4:331
10. Poggesi I, Jannuzzo MG, diSalle E, Piscitelli G, Rocchetti M, Spinelli R, Broutin F, Ornati G, Massimini G (1999) Effect of food on pharmacokinetics (PK) and pharmacodynamics (PD) of exemestane (Aromasin, EXE). 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, 15-18 May 1999
11. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646
12. Spinelli R, Jannuzzo MG, Poggesi I, Frevola L, Broutin F, Cicioni P, Marrari P, LeCoz F (1999) Pharmacokinetics (PK) of Aromasin (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV) (abstract 1185). Proc ECCO. Eur J Cancer 35(S4):S295
13. Thurlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G (1997) Third line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicenter multinational study. Eur J Cancer 33:1767
14. Yoshitani T, Yagi H, Inotsume N, Yasuhara M (2002) Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull 25:1077-1083